ACCESS PACK EXPO XPRESS ONLINE TODAY
ACCESS PACK EXPO XPRESS ONLINE TODAY. Content is available on-demand through November 30th.
LEARN MORE

FDA Approves First Biologic for Kids with Eczema

The subcutaneous injection is intended for patients 6 months to 5 years affected by atopic dermatitis.

Sanofi
Sanofi

Atopic dermatitis, aka eczema, affects more than 10% of Americans of all ages. It’s characterized by inflammation that causes dry, itchy patches on the skin. Though not life-threatening, it can be a painful nuisance and lead to dermal infections. According to a recent Everyday Health article, the FDA just approved the first biologic intended to treat the condition in kids ages 6 months to 5 years.

The drug, Sanofi’s Dupixent, is administered as a monthly injection under the skin at different sites. More than half the kids who participated in the drug’s trial saw a 75% reduction in the severity of the disease. 

Access On-Demand Content Today
Discover innovative solutions for packaging and processing, automation, sustainability, e-commerce and more.
LEARN MORE
Access On-Demand Content Today
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub